Sibold William John 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Madrigal (MDGL) CEO William Sibold Sells 1,577 Shares
What Happened
- William John Sibold, President & CEO and a Director of Madrigal Pharmaceuticals (MDGL), sold 1,577 shares on 2026-01-26 at $492.42 per share, generating about $776,546. This was a sale (S) and not a new purchase, and it reflects a routine disposition rather than an expressed market view.
Key Details
- Transaction date and price: 2026-01-26, 1,577 shares at $492.42 each.
- Total proceeds: approximately $776,546.
- Shares owned after transaction: not provided in the supplied filing summary.
- Footnote: The sale was automatic to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs); it was not at the Reporting Person’s discretion (per footnote F1).
- Filing timing: Reported on Form 4 with the same report date (2026-01-26), indicating the filing was made the same day as the reported transaction.
Context
- This was a tax-withholding/cashless-type sale tied to RSU vesting, a common administrative action that does not necessarily signal bullish or bearish intent by the insider. Retail investors typically weight purchases more heavily than routine withholding sales when assessing insider sentiment.
Insider Transaction Report
Form 4
Sibold William John
DirectorPresident and CEO
Transactions
- Sale
Common Stock
[F1]2026-01-26$492.42/sh−1,577$776,546→ 148,497 total
Footnotes (1)
- [F1]This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
Signature
/s/ Mardi Dier, as Attorney-in-Fact|2026-01-26